发明名称 AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS
摘要 1. Compound represented by the formula: wherein n represents 1 or 2; R<1> represents alkyl of 1-5 carbon atoms, alkenyl of 2-5 carbon atoms, alkynyl of 2-5 carbon atoms, hydroxyalkyl of 1-3 carbon atoms, alkoxyalkyl of 1-3 alkyl and 1-3 alkoxy carbon atoms, cyanoalkyl of 1-3 alkyl carbon atoms, imidazolylmethyl, -CH2 CONH2,-CH2 CH2CONH2, -CH2S(O)2NH2, -CH2 SCH3, -CH2S(O)CH3, -CH2S(O)2CH3, -C(CH3)2SCH3, -C(CH3)2S(O)CH3 or -C(CH3)3S(O)2CH3 radicals; R<2> represents radicals of alkyl of 1-5 carbon atoms, aralkyl of 1-3 alkyi carbon atoms, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthioalkyl of 1-3 alkyl carbon atoms or cycloalkylalkyl of 1-3 alkyl carbon atoms and 3-6 ring member carbon atoms; R<3> represents radicals of alkyl radical of 1-5 carbon atoms, cycloalkyl of 5-8 ring members or cycloalkylmethyl radical of 3-6 ring members; R<4> represents aryl, benzo fused 5 to 6 ring member heteroaryl or benzo fused 5 to 6 ring member heterocycio radicals; or a radical of the formula wherein A and B each independently represent O, S, SO or SO2; R<6> represents deuterium, alkyl of 1-5 carbon atoms, fluoro or chloro radicals; R<7> represents hydrogen, deuterium, methyl, fluoro or chloro radicals; or a radical of the formula wherein Z represents O, S or NH; and R<9> represents a radical of formula wherein Y represents O, S or NH; X represents a bond, C or NR<21>; R<20> represents hydrogen, alkyl of 1 to 5 carbon atoms, alkenyl of 2 to 5 carbon atoms, alkynyl of 2 to 5 carbon atoms, aralkyl of 1 be 5 alkyl carbon atoms, hetercaralkyl of 5 to 6 ring members and 1 to 5 alkyl carbon atoms, heterocycloalkyl of 5 to 6 ring members and 1 to 5 alkyl carbon atoms, aminoalkyl of 2 to 5 carbon atoms, N-mono-substituted or N,N-disubstituted aminoalkyl of 2 to 5 alkyl carbon atoms wherein said substituen.ts are radicals of alkyl of 1 to 3 carbon atoms, aralkyl of 1 to 3 alkyl carbon atoms radicals, carboxyalkyl of 1 to 5 carbon atoms, alkoxycarbonylalkyl of 1 to 5 alkyl carbon atoms, cyanoalkyl of 1 to 5 carbon atoms or hydroxyalkyl of 2 to 5 carbon atoms; R<21> represents hydrogen radical or alkyl radical of 1 to 3 carbon atorms; or.the radica1 of formula -NR<20>R<21> represents a 5 to 6 ring member heterocycicl radical; and R<22> represents alkyl radical of 1 to 3 carbon atoms or R<20>'R<21>lN-alkyl radical of 1 to 3 alkyl carbon atoms; R<10> represents hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; R<11> represents hydrogen, alkyl of 3-5 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, alkoxyalkyl of 1-3 alkyl carbon atoms, benzyl, imidazolylmethyl, -CH2CH2CONH2, -CH2CONH2, -CH2 CH2SCH3 or -CH2SCH3 radicals or the sulfone or sulfoxide derivatives thereof; R<12> represents hydrogen, hydroxyalkyl cr alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; and R<13> and R<14> each independently represent-t hydrogen, hydroxy, alkoxy, 2-hydroxyethoxy, hydroxyalky1 or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; or R<12> and R<13> or R<13> and R<14> along with the carbon atoms to which they are attached represent 5-6 ring membered heteroaryl or benzo radical, each of which is optionally substituted with at least one hydroxy or alkoxy radical of 1-3 carbon atoms. 2. Compound of Claim 1 wherein R<1> represents alkyl of 1-4 carbon atoms, alkenyl of 2-3 carbon atoms, alkynyl of 3-4 carbon atoms, cyanomethyl, imidazolylmethyliciidazolylmethyl, -CH2 CONH2, -CH2CH2CONH2, -CH2S(O)2NH2, -CH2 SCH3, -CH2S(O)CH3, -CH2S(O)2CH3, -C(CH3)2SCH3, -C(CH3)2S(O)CH3 or -C(CH3)3S(O)2CH3 radicals; and R<2> represents radicals of alkyl of 3-5 carbon atoms, arylmethyl, alkylthioalkyl of 1-3 alkyl carbon atoms, arylbhiomethyl or cycloalkylmethyl of 5-6 ring member carbon atoms radicals; R<3> represents alkyl of 1-5 carbon- atoms, cycaloalkylmethyl of 3-6 ring members, cyclohexyl or cycloheptyl radicals; R<4> represents phenyl, 2-naphthyl, 4-methoxyphenyl, 4-hydroxyphenyl, 3,4-dimethoxyphenyl, 3-aminophenyl, 4-aminohenyl, 2-amino-benzothiazol-5-yl, 2-aminobenzothiazol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzoxazol-5-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl or 1,4-benzodioxan-6-yl radicals; or a radical of the formula wherein A and B each represent 0; R<6> represents deuterium, methyl, ethyl, propyl, isopropyl or fluoro radicals; and R<7> represents hydrogen, deuterium, methyl or fluoro radicals; or a radical of the formula wherein Z represents O, S or NH; and R<9> represents a radical of formula wherein Y represents O, S or NH; X represents a bond, O or NR<21>; R<20> represents hydrogen, alkyl of 1 to 5 carbon atoms, phenylalkyl of 1 to 3 alkyl carbon atoms, heterocycloalkyl of 5 to 6 ring members and 1 to 3 alkyl carbon atoms, or N-mono-substituted or N,N-disubstituted aminoalkyl of 2 to 3 alkyl carbon atoms wherein said substituents are alkyl radicals of 1 to 3 carbon atoms; and R<21> represents hydrogen or methyl radicals; or the radical of formula -NR<20>R<21> represents pyrrolidinyl, piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, morpholinyl or thiamorpholinyl radicals; and R<22> represents alkyl radical of 1 to 3 carbon atoms. 3. Compound of Claim 2, wherein R<1> represents iso-propyl, sec-butyl, tert-butyl, 3-propynyl, imidazolylmethyl, -CH2CONH2, -CH2 SCH3, -CH2S(O)CH3, -CH2S(O)2CH3, -C(CH3)2SCH3 -C(CH3)2S(O)CH3 or -C(CH3)2S(O)2CH3 radicals; R<2> represents isobutyl, n-butyl, CH3SCH2CH2-, phenylthiomethyl, (2-naphthylthio)methyl, benzyl, 4-methoxyphenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals; R<3> represents propyl, isoarnyl, isobutyl, butyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexythyl radicals; R<4> represents phenyl, 2-naphthyl, 4-methoxyphenyl, 4-hydroxyphenyl, benzofchiazol-5-yl, benzothiazol-6-yl, benzoxazol-5-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-l,3-benzodioxol-5-yl, 2,2-dimethyl-l,3-benzodioxol-5-yl, 2,2-dideutero-l,3-benzodioxol-5-yl, 2,2-difluoro-l,3-benzodioxol-5-yl or 1,4-benzodioxan-6-yl radicals; or a radical of the formula wherein Z represents O, S or NH; and R<9> represents a radical of formula wherein Y represents O, S or NH; X represents a bond, O or NR<21>; R<20> represents hydrogen, methyl, ethyl, propyl, isopropyl, isobutyl, benzyl, 2-(1-pyrrolidinyl)ethyl, 2-(1-piperidinyl)ethyl, 2-(1-piperazinyl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, 2-(1-morpholinyl)ethyl, 2-(1-thiamorpholinyl)ethyl or 2-(N/N-dimethylamino)ethyl radicals ; R<21> represents a hydrogen radical; and R<22> represents methyl radical; R<10> and R<12> each represent hydrogen radical; R<11> represents hydrogen, methyl, isopropyl, butyl, secbutyl, isobutyl, hydroxymethyl or hydroxyefchyl radicals; and R<13> and R<14> each independently represent hydrogen, hydroxy, methoxy or ethoxy radicals; or R<12> and R<13> or R<13> and R<14> along with the carbon atoms to which they are attached represent benzo radical, which is optionally substituted with at least one hydroxy or methoxy radical. 4. Compound of Claim, wherein n represents 1; R<1> represents sec-butyl, tert-butyl, iso-propyi, 3-propynyl or -C(CH3)2S(O)2CH3 radicals; R<2> represents benzyl, 4-fluorophenylmethyl or cyclohexylmefchyl radicals; R4 represents phenyl, 4-methoxyphenyl, 4-hydroxyphenyl, benzothiazol-5-yl, benzothiazol-6-yl, 2,3-dihydrobenzofuran-5-yl, benzofuran-5-yl, 1,3-benzodioxol-5-yl, 2-methyl-l,3-benzodioxol-5-yl, 2,2-dimethyl-1,3-benzodioxol-5-yl, 2,2-dideutero-l,3-benzodioxol-5-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2-(methoxycarbonylamino)benzothiazol-6-yl or 2-(mefchoxycarbonylamino)benzimidazol-5-yl radicals; R<11> represents a hydrogen radical; and R<13> and R<14> each independently represent hydrogen, hydroxy, methoxy or ethoxy radicals. 5. Compound of Claim 1, wherein said pharmaceutically acceptable salt is hydrochloric acid salt, sulphuric acid salt, phosphoric acid salt, oxalic acid salt, maleic acid salt, succinic acid salt, citric acid salt or methanesulfonic acid salt. 6. Compound of Claim 5, wherein said pharmaceutically acceptable salt is hydrochloric acid salt, oxalic acid salt, citric acid salt or methanesulfonic acid salt. 7. Compound of Claim 1, which is 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino] 1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino] 1S-(phenylmethyl)propyl]-3-methyl-butanamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino] 1S-(phenylmethyl)propyl]-3S-methyl-pentanamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-30 [[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino] 1S-(phenylmethyl)propyl]-4-pentynamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[phenylsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; 2S-[[(pyrrolidin-l-yl)acefcyl]amino] -N- [2R-hydroxy-3-[[phenylsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3-methyl-butanamide; 2S-[[(pyrrolidin-l-yl)acefcyl]amino]-N-[2R-hydroxy-3-[[phenylsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3 S-methyl-pentanamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-10 [[phenylsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl) propyl]-4-pentynamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3-methyl-butanamide; 2S-[[(pyrrolidin-l-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3S-methyl-pentanamide; 2S-[[(pyrrolidin-1-yl) acetyl]amino ]-N-[2R-hydroxy-3-[[ (4-methoxyphenyl)sulfony
申请公布号 EA000470(B1) 申请公布日期 1999.08.26
申请号 EA19970000221 申请日期 1996.03.07
申请人 G.D. SEARLE &AMP;CO 发明人 GETMAN, DANIEL, P.;DECRESCENZO, GARY, A.;FRESKOS, JOHN, N.;VAZQUEZ, MICHAEL, L.;SIKORSKI, JAMES, A.;DEVADAS, BALEKUDRU;NAGARAJAN, SRINIVASAN;BROWN, DAVID, L.;MCDONALD, JOSEPH. J.
分类号 C07D317/46;A61K31/357;A61K31/36;A61K31/4025;A61K31/4035;A61K31/4184;A61K31/423;A61K31/426;A61K31/428;A61K31/4439;A61K31/454;A61K31/4709;A61K31/4725;A61K31/496;A61K31/5377;A61K31/541;A61K38/00;A61P31/12;A61P31/18;A61P43/00;C07D235/30;C07D263/56;C07D277/62;C07D277/82;C07D307/79;C07D311/58;C07D317/58;C07D317/62;C07D319/18;C07D339/06;C07K5/06;C07K5/08 主分类号 C07D317/46
代理机构 代理人
主权项
地址